Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ArriVent BioPharma (AVBP) Change in Account Payables (2023 - 2026)

ArriVent BioPharma has reported Change in Account Payables over the past 4 years, most recently at $2.8 million for Q1 2026.

  • Quarterly results put Change in Account Payables at $2.8 million for Q1 2026, up 382.3% from a year ago — trailing twelve months through Mar 2026 was $4.4 million (up 2029.76% YoY), and the annual figure for FY2025 was $2.1 million, up 385.09%.
  • Change in Account Payables reached $2.8 million in Q1 2026 per AVBP's latest filing, up from -$8000.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $3.7 million in Q2 2023 and bottomed at -$2.2 million in Q3 2023.
  • Median Change in Account Payables over the past 4 years was -$8000.0 (2025), compared with a mean of $428923.1.
  • The largest annual shift saw Change in Account Payables tumbled 393.22% in 2024 before it skyrocketed 382.3% in 2026.
  • Over 4 years, Change in Account Payables stood at $295000.0 in 2023, then crashed by 393.22% to -$865000.0 in 2024, then skyrocketed by 99.08% to -$8000.0 in 2025, then surged by 35187.5% to $2.8 million in 2026.
  • Business Quant data shows Change in Account Payables for AVBP at $2.8 million in Q1 2026, -$8000.0 in Q4 2025, and $1.9 million in Q3 2025.